According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

EC approval decision anticipated in second quarter of 2025PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech (KRYS – Research Report) and ...

Investors might want to bet on Krystal Biotech, Inc. (KRYS), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price ...

Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare ...

Krystal Biotech (KRYS) welcomed the European Medicines Agency’s announcement that its Committee for Medicinal Products for Human Use has issued ...

Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement ...

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have been given an average recommendation of “Buy” by the ...

PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the ...

South Side-based biotechnology firm Krystal Biotech Inc.'s stock is up 20% following its earnings call this morning.